首页> 外文期刊>The Indian journal of tuberculosis >Thyroid profile status of patients treated for multidrug-resistant tuberculosis in state of Meghalaya, India
【24h】

Thyroid profile status of patients treated for multidrug-resistant tuberculosis in state of Meghalaya, India

机译:印度梅加拉亚邦接受多药耐药结核病治疗的患者的甲状腺状况

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Meghalaya has high tuberculosis burden with increasing multidrug-resistant tuberculosis (MDR-TB) cases. Drug-induced hypothyroidism is one of the well-documented adverse effects in treatment of MDR-TB, the data of which are unavailable in the population residing in this part of the Indian subcontinent. Aim: This study was undertaken to assess the thyroid profile status of patients under DOTS Plus treatment and to evaluate the effects of anti-tubercular drugs on thyroid functions with respect to the pre-treatment thyroid status. Methods: A prospective study of 114 patients who initiated treatment for MDR-TB between June 2012 and August 2013 was performed. Thyroid hormones, viz., TSH, Total T3, Total T4, Free T3 and Free T4 were estimated. Results: Out of our study group of 114 MDR-TB patients, 15 dead patients and defaulters were excluded. So, out of 99 patients, till now, 76 patients have completed 6 months of DOTS Plus treatment and were re-evaluated for thyroid status. 52(68%) patients showed TSH levels more than the reference limit of 5.60 |xIU/mL and 5(7%) patients had TSH >10 muIU/mL suggesting presence of sub-clinical hypothyroidism. Conclusion: We suggest the need for Mandatory TSH screening at baseline and then six months interval for all patients taking DOTS Plus so that no adverse effect goes under-reported and early intervention if required should be done to maintain proper adherence.
机译:背景:梅加拉亚邦(Meghalaya)的结核病负担高,多重耐药结核病(MDR-TB)病例增加。药物诱发的甲状腺功能减退症是治疗耐多药结核病的有据可查的不良反应之一,在印度次大陆这一部分地区的人群中尚无相关数据。目的:本研究旨在评估接受DOTS Plus治疗的患者的甲状腺状况,并评估抗结核药物对治疗前甲状腺状况的影响。方法:对2012年6月至2013年8月开始治疗耐多药结核病的114例患者进行了一项前瞻性研究。估计甲状腺激素,即TSH,总T3,总T4,游离T3和游离T4。结果:在我们的114名耐多药结核病患者研究组中,排除了15例死亡患者和违法者。因此,到目前为止,在99例患者中,有76例患者完成了6个月的DOTS Plus治疗,并重新评估了甲状腺状况。 52(68%)患者的TSH水平高于参考限值5.60 | xIU / mL,而5(7%)患者的TSH> 10 muIU / mL,表明存在亚临床甲减。结论:我们建议对所有服用DOTS Plus的患者在基线时进行强制性TSH筛查,然后每六个月进行一次筛查,这样就不会出现不良反应报告不足的情况,如果需要,应进行早期干预以保持适当的依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号